EU advisory panel recommends approval of Amgen's Nplate

11/23/2008 | Forbes

The European Committee for Medicinal Products for Human Use endorsed approval of Amgen's Nplate, which treats a rare blood-clotting disease called idiopathic thrombocytopenia purpura. The drug, which works by boosting platelet production and preventing immune suppression in adults with chronic ITP, "will address an unmet medical need" in the region, an Amgen official said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC